IRB Study Number 24-814
Status Recruiting
Institute Taussig Cancer Institute
Description
Primary Objective:
To evaluate the effectiveness of immersive virtual reality during chemotherapy sessions in reducing distress in patients with high levels of distress from baseline diagnosed with any type of Cancer, using The NCCN Distress Thermometer.
Secondary Objectives:
To evaluate the effectiveness of immersive virtual reality in reducing anxiety using the Generalized Anxiety Disorder-7 item (GAD-7) and depression symptoms using the Cleveland Clinic Visual Analog Scale (CCVAS) in patients diagnosed with any stage or type of Cancer.
To evaluate the effectiveness of immersive virtual reality in reducing pain using the Universal Pain Assessment Tool.
To determine patients’ clinical and sociodemographic characteristics associated with significant changes after the
immersive virtual reality intervention.
Inclusion Criteria
I. Age ≥ 18 years.
II. Biopsy proven diagnosis of Cancer (any stage or type).
III. Must have a NCCN* Distress Thermometer Score ≥ 5 any time since diagnosis.
IV. Must be receiving a chemotherapy regimen.
V. Must have the ability to understand and the willingness to sign a written informed consent document.
VI. Followed by a medical oncologist, radiation oncologist, and/or breast surgeon at Cleveland Clinic.
VII. Ability to read and write in English or Spanish.
Exclusion Criteria
I. Age <18 years.
II. No prior history of Cancer.
III. Prior medical history of severe motion sickness.
IV. Prior medical history of seizures.
V. Use of cardiac pacemaker, hearing aid and/or defibrillator
VI. Pregnancy
VII. Unable or unwilling to participate in the immersive VR** study at the Maroone Cancer Center
